Successful treatment of hyperuricemia with low doses of recombinant urate oxidase in four patients with hematologic malignancy and tumor lysis syndrome
Authors:
Open Access
- 2 October 2003
- journal article
- other
- Published by Springer Nature in Leukemia
- Vol. 17 (12) , 2542-2544
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Elitek™–rasburicase: an effective means to prevent and treat hyperuricemia associated with tumor lysis syndrome, a Meeting Report, Dallas, Texas, January 2002Leukemia, 2003
- Pan-European multicentre economic evaluation of recombinant urate oxidase (rasburicase) in prevention and treatment of hyperuricaemia and tumour lysis syndrome in haematological cancer patientsSupportive Care in Cancer, 2003
- Recombinant urate oxidase (rasburicase) in the prevention and treatment of malignancy-associated hyperuricemia in pediatric and adult patients: results of a compassionate-use trialLeukemia, 2001
- Urate oxidase in the prophylaxis or treatment of hyperuricemia: The United States experienceSeminars in Hematology, 2001
- Urate oxidase in the prophylaxis or treatment of hyperuricemia: The United States experienceSeminars in Hematology, 2001
- A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysisBlood, 2001
- Recombinant Urate Oxidase for the Prophylaxis or Treatment of Hyperuricemia in Patients With Leukemia or LymphomaJournal of Clinical Oncology, 2001
- Nephropathy, xanthinuria, and orotic aciduria complicating Burkitt's lymphoma treated with chemotherapy and allopurinolMetabolism, 1972
- Xanthine Nephropathy in a Patient with Lymphosarcoma Treated with AllopurinolNew England Journal of Medicine, 1970